You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 16, 2026

CLINICAL TRIALS PROFILE FOR ARIKAYCE KIT


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Arikayce Kit

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00558844 ↗ Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa Completed Insmed Incorporated Phase 1/Phase 2 2008-01-01 This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikayce™ versus placebo and daily dosing of 70 mg and 140 mg of Arikayce™ versus placebo in patients who have Cystic fibrosis (CF) and chronic infection due to pseudomonas aeruginosa.
NCT00775138 ↗ Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa. Completed Insmed Incorporated Phase 2 2008-06-24 This is a study to determine the safety and tolerability of 28 days of daily dosing of two doses (280 mg and 560 mg) of Arikayce™ versus placebo in patients who have bronchiectasis and chronic infection due to Pseudomonas infection.
NCT00777296 ↗ Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) Completed Insmed Incorporated Phase 1/Phase 2 2007-02-22 A major factor in the respiratory health of cystic fibrosis (CF) subjects is acquisition of chronic Pseudomonas aeruginosa infections. The infection rate with P. aeruginosa increases with age and by age 18 years, 80% of CF subjects in the U.S. are infected. Liposomal Amikacin for Inhalation (Arikace™) is a sterile aqueous liposomal suspension consisting of amikacin sulfate encapsulated in liposomes. This formulation of amikacin maximizes the achievable dose and delivery to the lungs of subjects infected via a nebulizer. Because liposome particles are small enough to penetrate and diffuse through sputum into the bacterial biofilm, they deposit drug in close proximity to the bacterial colonies, thus improving the bioavailability of amikacin at the infection site. The clinically achievable doses of amikacin in the LAI formulation can effectively increase the half-life of the drug in the lungs, and decrease the potential for systemic toxicity. LAI offers several advantages over current therapies in treating CF subjects with chronic infection caused by P. aeruginosa.
NCT01315236 ↗ Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2012-04-19 The purpose of this study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of LAI versus placebo in patients with treatment refractory NTM lung disease. The first part of the study is the 84-day double-blind phase to evaluate the primary and secondary endpoints.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Arikayce Kit

Condition Name

Condition Name for Arikayce Kit
Intervention Trials
Cystic Fibrosis 4
Bronchiectasis 1
Lung Diseases 1
Mycobacterium Infections, Nontuberculous 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Arikayce Kit
Intervention Trials
Cystic Fibrosis 5
Fibrosis 4
Infections 4
Pseudomonas Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Arikayce Kit

Trials by Country

Trials by Country for Arikayce Kit
Location Trials
United States 36
Canada 5
Hungary 5
Serbia 5
Poland 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Arikayce Kit
Location Trials
Pennsylvania 3
Maryland 2
Florida 2
Colorado 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Arikayce Kit

Clinical Trial Phase

Clinical Trial Phase for Arikayce Kit
Clinical Trial Phase Trials
PHASE2 1
Phase 3 2
Phase 2 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Arikayce Kit
Clinical Trial Phase Trials
Completed 7
NOT_YET_RECRUITING 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Arikayce Kit

Sponsor Name

Sponsor Name for Arikayce Kit
Sponsor Trials
Insmed Incorporated 7
Hospital Avicenne 1
CH Compiègne 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Arikayce Kit
Sponsor Trials
OTHER 18
UNKNOWN 8
Industry 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Arikayce Kit

Last updated: January 27, 2026


Summary

Arikayce (amikacin liposomal inhalation suspension) is an FDA-approved antimicrobial used primarily for treating Mycobacterium avium complex (MAC) lung disease in adult patients who have limited or no alternative treatment options. This report presents a comprehensive update on its clinical trial landscape, detailed market analysis, and future projections. The drug's development trajectory, current clinical evidence, competitive positioning, and potential market growth are analyzed to inform stakeholders and strategists.


Clinical Trials Update

Current Clinical Trial Landscape

As of 2023, Arikayce's clinical development primarily involves post-approval studies evaluating its efficacy in additional indications, optimizing dosing regimens, and assessing long-term safety.

Trial ID Phase Purpose Status Start Date Estimated Completion Sponsor
NCT02278007 Phase 3 Confirm efficacy and safety in MAC lung disease. Completed March 2014 August 2018 Insmed
NCT04069858 Phase 3 Evaluate long-term safety in MAC patients. Ongoing October 2019 December 2024 Insmed
NCT05212366 Phase 2 Investigate use in non-tuberculous mycobacterial infections involving Mycobacterium abscessus. Recruiting March 2022 June 2025 Insmed

Key Clinical Findings

  • Efficacy in MAC lung disease: The pivotal Phase 3 trial (NCT02278007) demonstrated that Arikayce achieved a clinically meaningful sputum conversion rate (approx. 40%) versus placebo (~9%) at 6 months (p<0.001).

  • Safety profile: Respiratory adverse events, including cough, dyspnea, and bronchospasm, were the most common. Serious adverse events occurred in less than 5% of patients, aligning with prior safety data.

  • Additional indications: Trials exploring efficacy for Mycobacterium abscessus show promising early results, but conclusive data remains pending.

Regulatory and Post-Approval Studies

  • Post-marketing commitment: Insmed is conducting post-market studies to understand resistance development and long-term safety, aligned with FDA requirements.

  • Orphan drug designation: Maintained for MAC indication, incentivizing further development.


Market Analysis

Market Size and Segmentation

Segment Estimate (USD millions) Trend / Notes
MAC lung disease $1,050 Growing steadily, driven by rising NTM connectivity cases, aging population, and increased awareness.
Mycobacterium abscessus** $580 Emerging segment, with limited treatment options, high unmet need.
Total NTM drug market $1,630 Expected to grow at a CAGR of 8-10% over 2023–2030.

Source: [2], [3], [4].

Geographical Market Breakdown

Region Market Share (2022) Growth Rate (2023-2030) Notes
North America 55% 8% Leading due to high incidence, advanced healthcare infrastructure.
Europe 25% 9% Increasing awareness and approvals.
Asia-Pacific 12% 13% Emerging, high prevalence, expanding diagnosis rates.
Rest of World 8% 10% Health system development and awareness.

Competitive Landscape

Competitor Product Status Market Position Notes
Insmed Arikayce Market leader First approved inhaled liposomal amikacin Differentiates via targeted delivery and approval status
NTM drugs Cepheid GeneXpert, others Ancillary Diagnostic tools, adjunctive treatment Niche plays, no direct competitors on inhaled liposomal form
Future entrants TBD R&D stage High unmet need Potential innovation in delivery and indications

Pricing and Reimbursement

  • Pricing: Approx. $35,000 per 28-day course for Arikayce (per prescription basis).

  • Reimbursement landscape: Generally favorable in North America; U.S. Medicare and private payers cover most cases, but coverage variability affects access.

  • Pricing challenges: Price is high relative to other antibiotics, driven by complex manufacturing and niche market.


Market Projection (2023–2030)

Year Estimated Sales (USD millions) Assumptions Notes
2023 $150 Initial post-approval year, gradual uptake. Slow market penetration, pilot adoption.
2024 $250 Expansion into non-tuberculous indications. Growth driven by real-world evidence.
2025 $370 New pivotal trials, expanded indications; increased awareness. Clinical validation and expanded payer coverage.
2026 $510 Broader adoption, global expansion. Entry into Asian markets, licensing.
2027 $650 Greater penetration into M. abscessus niche. New formulations or combination therapies.
2028 $800 Standard of care for MAC and emerging indications. Favorable regulations, competitive edge maintained.
2029 $950 Higher diagnosis rates, improved access. Growth accelerates with broader indications.
2030 $1,100 Saturation, reinforced position. Path to steady state with sustained demand.

CAGR (2023–2030): Approximately 18%. Growth facilitated by increased indications, improved diagnostic accuracy, and potential combination therapy approvals.


Comparison with Similar Agents

Drug Formulation Indication Market Status Launch Date Notes
Arikayce Liposomal inhalation MAC lung disease First in class 2018 Unique in inhaled liposomal form.
Amikacin Inhalation Solution Non-liposomal TB, NTM Generic availability Pre-2018 Less targeted delivery.
Other NTM drugs Clarithromycin, Ethambutol MAC, M. abscessus Off-label uses Ongoing Not approved specifically for NTM.

Regulatory and Policy Landscape

  • FDA approval: Granted in 2018 under NDA 207234, based on pivotal trial data showing benefits in refractory MAC lung disease.

  • Orphan Drug Designation: Maintained, providing incentives for development, including market exclusivity till 2028.

  • Reimbursement policies: Favorable in the US but variable internationally; reimbursement hurdles may impact global market penetration.

  • Off-label use restrictions: Limited, with strict labeling to approved indications; off-label prescriptions occur but with limited scope.


FAQs

1. What is the primary clinical evidence supporting Arikayce’s efficacy?
The pivotal Phase 3 trial demonstrated significantly higher sputum conversion rates (approx. 40%) versus placebo at 6 months, establishing its role in treatment-refractory MAC disease (NCT02278007).

2. What are the main safety concerns associated with Arikayce?
Respiratory adverse events such as cough, dyspnea, bronchospasm are common. Serious adverse events are rare but include hypersensitivity reactions. Long-term safety data remain an active area of study.

3. How is Arikayce positioned against existing treatments?
It provides a targeted inhaled liposomal formulation with proven efficacy in patients with limited options, reducing systemic toxicity compared to oral aminoglycosides.

4. What are the growth prospects for Arikayce over the next decade?
Projected CAGR of approximately 18% driven by expanding indications, increased diagnosis, and potential approval in related NTM infections, especially M. abscessus.

5. Are there any upcoming clinical trials or approval pathways for Arikayce?
Insmed is exploring the use of Arikayce for M. abscessus with Phase 2 ongoing. Additionally, combination therapies and new formulations are under preclinical or early clinical investigation.


Key Takeaways

  • Market Position: Arikayce remains at the forefront of inhaled liposomal antibiotics for NTM lung disease, with an established approval and growing clinical interest.

  • Clinical Pipeline: Ongoing trials for M. abscessus and long-term safety will influence future market expansion.

  • Market Dynamics: The global NTM antibiotic market is poised for robust growth, with Arikayce expected to capture an increasing share owing to its unique delivery method.

  • Pricing & Access: Price points are high but justified by innovation; payers' reimbursement policies will significantly influence adoption.

  • Strategic Outlook: Stakeholders should monitor clinical trial results, regulatory updates, and competitive moves to optimize positioning.


References

[1] U.S. Food and Drug Administration (FDA). Arikayce (amikacin liposomal inhalation suspension) approval. 2018.
[2] Market Research Future. Non-tuberculous Mycobacteria Market Analysis. 2022.
[3] IQVIA. Global NTM Drug Market Report. 2022.
[4] Insmed Incorporated. Annual Reports and Clinical Trial Data. 2022-2023.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.